Heba K. Mohammed-Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heba K. Mohammed-Ahmed has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ayşen Tezcaner
Middle East Technical University
2 shared publications - Dilek Keskin
Middle East Technical University
2 shared publications - Mustafa Nakipoglu
Department of Molecular Biology and Genetics Faculty of Sciences Bartın University Bartın Turkiye
2 shared publications - Zafer Evis
Department of Engineering Sciences, Faculty of Engineering, Middle East Technical University, Ankara, Türkiye
2 shared publications
Latest Publications
- 24 January 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 80
Functionalization of graphene oxide quantum dots for anticancer drug delivery
- 24 January 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 80
Functionalization of graphene oxide quantum dots for anticancer drug delivery
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Functionalization of Graphene Oxide Quantum Dots for Anticancer Drug Delivery
Graphene quantum dots (GQDs) have a wide range of applications in biomedical applications, particularly anticancer drug delivery. In this study, graphene oxide quantum dots conjugated with glucosamine and boric acid (GOQDs-GlcN-BA) with and without anticancer drug were investigated for cancer therapy. FTIR, XRD, and SEM analyses were used to characterize graphene oxide (GO), and FTIR, ICP, and TEM were used to characterize GO quantum dots. The presence of various functional groups in the FTIR analysis demonstrated the successful synthesis of GO (hydroxyl, epoxy, carboxyl, etc). Furthermore, the FTIR analysis revealed that glucosamine was successfully conjugated. The nanocomposite contained 4 w/w boron according to the ICP analysis. Furthermore, the size of all the nanocomposites synthesized ranged between 15 and 51 nm. DOX loading efficiencies of GOQDs-GlcN-DOX and GOQDs-GlcN-BA-DOX were 57% and 90%, respectively. Only 8% of DOX release occurred from GOQDs-GlcN-DOX in acidic environment and 5% of drug released at neutral pH, whereas BA addition in the nanocomposite increased DOX release up to 20% at 5.5 pH and 10% at 7.4 pH in 96 h. GOQD-GlcN-BA-DOX exhibited more cytotoxicity against MCF-7 cells compared to GOQD-GlcN-DOX. Cellular internalization of GOQD-GlcN-BA-DOX in MCF-7 was higher than observed for GOQDs-GlcN-DOX owing to sialic acid on cell surface and BA interaction. This work shows the addition of BA enhanced the loading and release of anticancer drug to GOQDs-GlcN, with higher cellular internalization, thus superior potential for anticancer drug delivery.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessFunctionalization of Graphene Oxide Quantum Dots for Anticancer Drug Delivery
Graphene quantum dots (GQDs) have a wide range of applications in biomedical applications, particularly anticancer drug delivery. In this study, graphene oxide quantum dots conjugated with glucosamine and boric acid (GOQDs-GlcN-BA) with and without anticancer drug were investigated for cancer therapy. FTIR, XRD, and SEM analyses were used to characterize graphene oxide (GO), and FTIR, ICP, and TEM were used to characterize GO quantum dots. The presence of various functional groups in the FTIR analysis demonstrated the successful synthesis of GO (hydroxyl, epoxy, carboxyl, etc). Furthermore, the FTIR analysis revealed that glucosamine was successfully conjugated. The nanocomposite contained 4 w/w boron according to the ICP analysis. Furthermore, the size of all the nanocomposites synthesized ranged between 15 and 51 nm. DOX loading efficiencies of GOQDs-GlcN-DOX and GOQDs-GlcN-BA-DOX were 57% and 90%, respectively. Only 8% of DOX release occurred from GOQDs-GlcN-DOX in acidic environment and 5% of drug released at neutral pH, whereas BA addition in the nanocomposite increased DOX release up to 20% at 5.5 pH and 10% at 7.4 pH in 96 h. GOQD-GlcN-BA-DOX exhibited more cytotoxicity against MCF-7 cells compared to GOQD-GlcN-DOX. Cellular internalization of GOQD-GlcN-BA-DOX in MCF-7 was higher than observed for GOQDs-GlcN-DOX owing to sialic acid on cell surface and BA interaction. This work shows the addition of BA enhanced the loading and release of anticancer drug to GOQDs-GlcN, with higher cellular internalization, thus superior potential for anticancer drug delivery.